Trimodality treatment and selective organ preservation for bladder cancer

Journal of Clinical Oncology

Volumn 24, Issue 35, 2006, Pages 5536-5544

  Rödel, Claus ^a   Weiss, Christian ^a   Sauer, Rolf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; MOLECULAR MARKER; VINBLASTINE;

ADJUVANT THERAPY; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; EUROPE; HUMAN; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION; UNITED STATES; BLADDER TUMOR; MULTIMODALITY CANCER THERAPY; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 34247396980     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.6729     Document Type: Review

References (91)

1. Rodel C: Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 180:701-709, 2004
2. Shipley WU, Prout GR Jr, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258:931-935, 1987
3. Housset M, Maulard C, Chretien Y, et al: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993
4. Sauer R, Dunst J, Altendorf-Hofmann A, et al: Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 19:687-691, 1990
5. Kachnic LA, Kaufman DS, Heney NM, et al: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15:1022-1029, 1997
6. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993
7. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996
8. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 76:3576-3583, 1998
9. Zietman AL, Shipley WU, Kaufman DS, et al: A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 160:1673-1677, 1998
10. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471-476, 2000
11. Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665-672, 2003
12. Russell KJ, Boileau MA, Higano C, et al: Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 19:693-699, 1990
13. Rotman M, Aziz H, Porrazzo M, et al: Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion. Int J Radiat Oncol Biol Phys 18:1131-1137, 1990
14. Given RW, Parsons JT, McCarley D, et al: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 46:499-504, 1995
15. Housset M, Dufour B, Maulard-Durdux C, et al: Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 16:319a, 1997
16. Varveris H, Delakas D, Anezinis P, et al: Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma: A preliminary report of tolerance and local control. Anticancer Res 17:4771-4780, 1997
17. Fellin G, Graffer U, Bolner A, et al: Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 80:44-49, 1997
18. Cervek J, Cufer T, Zakotnik B, et al: Invasive bladder cancer: Our experience with bladder sparing approach. Int J Radiat Oncol Biol Phys 41:273-278, 1998
19. Zapatero A, Martin de Vidales C, Marin A, et al: Invasive bladder cancer: A single-institution experience with bladder-sparing approach. Int J Cancer 90:287-294, 2000
20. Arias F, Dominguez MA, Martinez E, et al: Chemoradiotherapy for muscle invading bladder carcinoma: Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47: 373-378, 2000
21. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061-3071, 2002
22. Chen WC, Liaw CC, Chuang CK, et al: Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56:726-733, 2003
23. Peyromaure M, Slama J, Beuzeboc P, et al: Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: Report of a single institution. Urology 63:73-77, 2004
24. Danesi DT, Arcangeli G, Cruciani E, et al: Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: Long term results. Cancer 101:2540-2548, 2004
25. Hussain SA, Stocken DD, Peake DR, et al: Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90:2106-2111, 2004
26. Kragelj B, Zaletel-Kragelj L, Sedmak B, et al: Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75:44-47, 2005
27. Dunst J, Diestelhorst A, Kuhn R, et al: Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 181:632-637, 2005
28. Greven KM, Solin LJ, Hanks GE: Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 65:908-912, 1990
29. Smaaland R, Akslen LA, Tonder B, et al: Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol 67:61-69, 1991
30. Moonen L, vd Voet H, de Nijs R, et al: Muscle-invasive bladder cancer treated with external beam radiation: Influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 42:525-530, 1998
31. Quilty PM, Kerr GR, Duncan W: Prognostic indices for bladder cancer: An analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 7:311-321, 1986
32. Pollack A, Zagars GK, Swanson DA: Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors. Int J Radiat Oncol Biol Phys 30:267-277, 1994
33. Shipley WU, Rose MA, Perrone TL, et al: Full-dose irradiation for patients with invasive bladder carcinoma: Clinical and histological factors prognostic of improved survival. J Urol 134:679-683, 1985
34. Pos FJ, Hart G, Schneider C, et al: Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 64:1168-1173, 2006
35. Naslund I, Nilsson B, Littbrand B: Hyperfractionated radiotherapy of bladder cancer: A ten-year follow-up of a randomized clinical trial. Acta Oncol 33:397-402, 1994
36. Goldobenko GV, Matveev BP, Shipilov VI, et al: Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol (Mosk) 36:14-16, 1991
37. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: Overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37:259-267, 1997
38. Maciejewski B, Majewski S: Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21:163-170, 1991
39. Horwich A, Dearnaley D, Huddart R, et al: A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 75:34-43, 2005
40. Kob D, Arndt J, Kriester A, et al: Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation. Strahlenther Onkol 161: 673-677, 1985
41. Henry AM, Stratford J, McCarthy C, et al: X-ray volume imaging in bladder radiotherapy verification. Int J Radiat Oncol Biol Phys 64:1174-1178, 2006
42. Pos FJ, Hulshof M, Lebesque J, et al: Adaptive radiotherapy for invasive bladder cancer: A feasibility study. Int J Radiat Oncol Biol Phys 64:862-868, 2006
43. Pos F, Horenblas S, Dom P, et al: Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 61:678-686, 2005
44. Hata M, Miyanaga N, Tokuuye K, et al: Proton beam therapy for invasive bladder cancer: A prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 64:1371-1379, 2006
45. Coppin CM, Gospodarowicz MK, James K, et al: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2901-2907, 1996
46. Patel B, Forman J, Fontana J, et al: A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys 62:1332-1338, 2005
47. Dunst J, Weigel C, Heynemann H, et al: Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 175Suppl 37-10, 1999
48. Nichols RC Jr., Sweetser MG, Mahmood SK, et al: Radiation therapy and concomitant paclitaxel/ carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: A well-tolerated combination. Int J Cancer 90:281-286, 2000
49. Kent E, Sandler H, Montie J, et al: Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial. J Clin Oncol 22:2540-2545, 2004
50. Sangar VK, McBain CA, Lyons J, et al: Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 61:420-425, 2005
51. Kaufman DS, Winter KA, Shipley WU, et al: Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. J Clin Oncol 23:379s, 2005 (abstr)
52. Hoskin PJ, Saunders MI, Phillips H, et al: Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 76:260-263, 1997
53. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, et al: Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125-132, 2000
54. Bellmunt J, Hussain M, Dinney CP: Novel approaches with targeted therapies in bladder cancer: Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46:85-104, 2003
55. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al: Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 142:1448-1454, 1989
56. Agerbaek M, Alsner J, Marcussen N, et al: Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer 89:298-304, 2003
57. Chakravarti A, Winter K, Wu CL, et al: Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62: 309-317, 2005
58. Chyle V, Pollack A, Czerniak B, et al: Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 35:281-287, 1996
59. Cooke PW, James ND, Ganesan R, et al: Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 85:829-835, 2000
60. Garcia del Muro X, Condom E, Vigues F, et al: p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100:1859-1867, 2004
61. Harada S, Sato R, Nakamura R, et al: The correlation between spontaneous and radiation-induced apoptosis in T3B bladder cancer (histological grade G3), and the precedence between the two kinds of apoptosis for predicting clinical prognosis. Int J Radiat Oncol Biol Phys 48:1059-1067, 2000
62. Hussain SA, Ganesan R, Hiller L, et al: BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 10:571-576, 2003
63. Jahnson S, Risberg B, Karlsson MG, et al: p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 28:135-142, 1995
64. Lara PC, Perez S, Rey A, et al: Apoptosis in carcinoma of the bladder: Relation with radiation treatment results. Int J Radiat Oncol Biol Phys 43:1015-1109, 1999
65. Lara PC, Rey A, Santana C, et al: The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol 49:163-167, 1998
66. Moonen L, Ong F, Gallee M, et al: Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 49:1305-1310, 2001
67. Ogura K, Habuchi T, Yamada H, et al: Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: Positive immunostaining and radiosensitivity. Int J Urol 2:302-308, 1995
68. Ong F, Moonen LM, Gallee MP, et al: Prognostic factors in transitional cell cancer of the bladder: An emerging role for Bcl-2 and p53. Radiother Oncol 61:169-175, 2001
69. Osen I, Fossa SD, Majak B, et al: Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: An immunohistochemical study. Br J Urol 81:862-869, 1998
70. Pollack A, Czerniak B, Zagars GK, et al: Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 39:687-695, 1997
71. Pollack A, Wu CS, Czerniak B, et al: Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3:1823-1829, 1997
72. Qureshi KN, Griffiths TR, Robinson MC, et al: Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 51:1234-1240, 2001
73. Rodel C, Grabenbauer GG, Rodel F, et al: Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46:1213-1221, 2000
74. Rotterud R, Berner A, Holm R, et al: p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int 88:202-208, 2001
75. Weiss C, Rodel F, Wolf I, et al: Combined-Modality Treatment and Organ Preservation in Bladder Cancer Do Molecular Markers Predict Outcome? Strahlenther Onkol 181:213-222, 2005
76. Wu CS, Pollack A, Czerniak B, et al: Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47: 305-310, 1996
77. Hoskin PJ, Sibtain A, Daley FM, et al: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89:1290-1297, 2003
78. Sak SC, Harnden P, Johnston CF, et al: APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 11:6205-6211, 2005
79. Manoharan M, Soloway MS: Optimal management of the T1G3 bladder cancer. Urol Clin North Am 32:133-145, 2005
80. Weiss C, Wolze C, Engehausen DG, et al: Radiochemotherapy after transurethral resection for high-risk t1 bladder cancer: An alternative to intravesical therapy or early cystectomy? J Clin Oncol 24:2318-2324, 2006
81. Zietman AL, Grocela J, Zehr E, et al: Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58:380-385, 2001
82. Shipley WU, Kaufman DS, Zehr E, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60: 62-68, 2002
83. Bochner BH, Figueroa AJ, Skinner EC, et al: Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 160:29-33, 1998
84. Henningsohn L, Wijkstrom H, Dickman PW, et al: Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62:215-225, 2002
85. Zietman AL, Sacco D, Skowronski U, et al: Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170:1772-1776, 2003
86. Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: A contemporary series. J Urol 165:1111-1116, 2001
87. Matsumoto H, Wada T, Fukunaga K, et al: Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 34:124-130, 2004
88. Rotterud R, Pettersen EO, Berner A, et al: Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients. Acta Oncol 41:463-470, 2002
89. Hug EB, Donnelly SM, Shipley WU, et al: Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: A possible predictor for successful bladder preservation following transurethral surgery and chemotherapy- radiotherapy. J Urol 148:47-51, 1992
90. Jenkins BJ, Martin JE, Baithun SI, et al: Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol 65:345-348, 1990
91. Wijkstrom H, Tribukait B: Deoxyribonucleic acid flow cytometry in predicting response to radical radiotherapy of bladder cancer. J Urol 144:646-650, 1990